ýҕl

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • ýҕl Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

TRENDING TOPICS:

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Apr 14 2026

Full Issue

Pill For Metastatic Pancreatic Cancer Helped Patients Live Twice As Long

Stat reported that patients who took the daily pill, called daraxonrasib, lived a median of 13.2 months compared with 6.7 months for patients who received chemotherapy. One of the trial's participants, former U.S. Sen. Ben Sasse of Nebraska, said, "This experience has seemingly extended both quantity and quality of [my] life.”

Metastatic pancreatic cancer patients who received a targeted pill from Revolution Medicines lived nearly twice as long as patients who received chemotherapy, a striking result in an especially deadly and intractable malignancy. Patients who took the daily pill, called daraxonrasib, lived a median of 13.2 months, compared to 6.7 months for patients who received chemotherapy. (Mast, 4/13)

When Ben Sasse, a former United States senator (R-Neb.), learned he had metastatic pancreatic cancer, he quickly chose action over comfort. Whatever he could do to save his life, for as long as he could, he wanted to try it. Perhaps his only option, doctors told him, was to enroll in a clinical trial. (Chen, 4/14)

More news about cancer —

People who survived cancer as teens and young adults are at increased risk of developing cancer later in their lives, according to research from the Canadian Medical Association Journal. Approximately 16% of adolescent and young adult cancer survivors who stayed cancer-free for at least five years are at high risk, compared to about 12% of people in the same age group without cancer. (Negussie, 4/13)

Anemia, a common blood disorder, may be a major risk factor for developing cancer. That's according to new research from Sweden, which sought to discover whether newly developed anemia is an early warning sign of cancer or death from any cause. (Stabile, 4/13)

A negative study in low-grade serous ovarian cancer might have uncovered a pathway toward more effective treatment for a large subgroup of patients, according to the NRG-GY019 trial. (Bankhead, 4/12)

A small, red "miracle fruit" is gaining attention for its ability to make lemons taste like lemonade — and for helping some cancer patients cope with an unpleasant side effect of treatment. (Bardolf, 4/13)

Also —

ESPN college basketball broadcaster Dick Vitale announced Monday that he has been diagnosed with melanoma in his lung and liver cavity. Vitale, 86, will soon start immunotherapy treatments. The legendary ESPN personality has been ravaged by health struggles in recent years, battling multiple forms of cancer. (Williams, 4/13)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
More Morning Briefings
RSS Feeds
  • ýҕl
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF